This article is more than 5 years old. Information may no longer be current.
Recent updates in atopic dermatitis for National Eczema Awareness Month
Click Here to Manage Email Alerts
An estimated 16.5 million adults in the U.S. have atopic dermatitis, according to the Asthma and Allergy Foundation of America.
To spread awareness during National Eczema Awareness Month, below is summary of recent news updates in eczema research and treatment options at Healio Dermatology.
Atopic eczema linked with increase in new depression, anxiety
Treated atopic eczema was associated with a 14% increase in the risk for newly diagnosed depression and a 17% increase in a subsequent anxiety diagnosis, regardless of eczema severity, according to a study. Read more
Cell dysregulation may play role in development, exacerbation of head and neck dermatitis
The exacerbation or development of head and neck dermatitis in patients treated for atopic dermatitis with dupilumab may be caused by a dysregulation in the balance of the T helper cell signaling pathway, according to a research letter in JAMA Dermatology. Read more
With perspective from Peter Lio, MD, clinical assistant professor of dermatology and pediatrics at Northwestern University Feinberg School of Medicine.
Dupilumab significantly improves atopic dermatitis in Asian, black and white patients
Dupilumab significantly improved atopic dermatitis signs, symptoms and quality of life in Asian, black and white patients, according to a pooled analysis of three phase 3 trials. Read more
With perspective from Peter Lio, MD.
Glenmark receives FDA approval for generic atopic dermatitis cream
The FDA has granted final approval for pimecrolimus cream 1%, a generic form of Elidel, according to an announcement from Glenmark Pharmaceuticals. Read more
Moderate to severe atopic dermatitis may increase risk for atrial fibrillation
Patients with moderate to severe atopic dermatitis had a 20% increase in the long-term risk for atrial fibrillation although the absolute risk remains low, according to findings from a 35-year cohort study. Read more
Baricitinib meets primary endpoint in adults with atopic dermatitis
Baricitinib met the primary endpoint in adults with moderate to severe atopic dermatitis in BREEZE-AD7, the third pivotal phase 3 trial of the BREEZE-AD program, which is expected to be completed later this year. Read more
Long-term dupilumab treatment safe, effective for atopic dermatitis
Dupilumab showed consistent and sustained efficacy in an open-label extension study in adults previously enrolled in 12 parent studies assessing dupilumab in moderate to severe atopic dermatitis. Read more